p21WAF1 (p21) and p27KIP1 (p27) are both universal inhibitors of cyclin-dependent kinases
and can therefore influence cell cycle or tumor progression.
The cyclins and cyclin-dependent kinase
inhibitors in normal regulation of proliferation and differentiation.
Expression of cyclin E and the cyclin-dependent kinase
inhibitor p27 in malignant lymphomas--prognostic implications.
Genes essential for the yeast's survival would turn on only when the added DNA caused the yeast to produce a protein that bound to cyclin-dependent kinase
, also a protein.
M2 PHARMA-September 6, 2017-MEI Pharma Inc acquires oral and selective cyclin-dependent kinase
(CDK) inhibitor voruciclib for the proposed treatment of CLL
The product is a selective cyclin-dependent kinase
inhibitor that has been approved as initial endocrine-based therapy to treat postmenopausal women with hormone receptor positive and human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.
This Cyclin-dependent Kinase
Inhibitor (CKI) pathway plays an important role in cancer and a range of diseases associated with the aging process, such as Alzheimer's disease, renal disease, atherosclerosis and arthritis.
The present Competitive Intelligence Report about Novel Mitotic Kinase Inhibitors provides a competitor evaluation in the field of synthetic molecules targeting polo-like kinase 1 (Plk-1), cyclin-dependent kinase
(CDK) or aurora kinase for treatment of cancer as of June 2009.
The RGB-286638 compound has been shown to inhibit the processes controlling cell division in cancer cells by targeting multiple cyclin-dependent kinase
proteins involved in regulating the cell cycle.
The US Food and Drug Administration has accepted and filed US-based pharmaceutical company Eli Lilly and Co's (NYSE: LLY) New Drug Application for abemaciclib, a cyclin-dependent kinase
4 and 6 inhibitor, and given the NDA a Priority Review designation, the company said.
The first patient has been dosed in the Phase 1 clinical trial of SY-1365, US-based biopharmaceutical company Syros Pharmaceuticals (NASDAQ: SYRS) first-in-class selective cyclin-dependent kinase
7 inhibitor, in patients with advanced solid tumors, including transcriptionally dependent cancers such as triple negative breast, small cell lung and ovarian cancers, the company said.
It was reported yesterday that the collaboration is aimed at assessing the safety and efficacy of combining investigational agent RAD1901, a novel oral selective estrogen receptor degrader, with investigational agent LEE011, a cyclin-dependent kinase